PARKINSON'S DISEASE NEWS
Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail firstname.lastname@example.org.
LOW RESOLUTION VERSION : There is a low resolution version of this web page INTENDED FOR THOSE PEOPLE THAT EITHER : use 800x600 resolution on their monitors, or have eyesight difficulties, or have slow INTERNET SPEEDS. GO TO LOW RESOLUTION VERSION
21st May 2013 - New research
PEPPERS REDUCE THE RISK OF PARKINSON'S DISEASE
Annals of Neurology  May 9 [Epub ahead of print] (Nielsen SS, Franklin GM, Longstreth WT, Swanson PD, Checkoway H.) Complete abstract
Nicotine has long been known to reduce the risk of Parkinson's Disease. So researchers assessed whether the risk of Parkinson's Disease is associated with the consumption of nicotine-containing vegetables edibles from the same botanical family as tobacco, Solanaceae, which includes peppers, tomatoes, and potatoes.
When people with Parkinson's Disease were compared with those people that did not have it, Parkinson's Disease was found to be less likely in those people that ate more peppers, tomatoes, tomato juice, and potatoes during adulthood. An association was also found for just peppers. The likelihood of developing Parkinson's Disease was an average of 81% as likely, and in some people down to 65% as likely. The association was intensified when the nicotine concentration of the vegetables was higher. So it was nicotine that caused the effect. The potential effect largely occurred in people who had never used tobacco or who had smoked cigarettes for less than 10 years.
Consumption of other vegetables was unrelated to the likelihood of developing Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
17th May 2013 - New research
PRELADENANT CLINICAL TRIAL RESULTS FOR PARKINSON'S DISEASE
Movement Disorders  Apr 15 [Epub ahead of print] (S.A.Factor, K.Wolski,
D.M.Togasaki, S.Huyck, M. Cantillon, T.W.Ho, R.A.Hauser, E.Pourcher)
Preladenant was taken in 5mg dosages twice a day alongside L-dopa for nine months. Adverse reactions caused 14% of people to cease taking it. Adverse reactions experienced by some people were dyskinesia and constipation. Preladenant provided reductions in "off" time by between 1 hour 24 minutes and 1 hour 54 minutes. "On" time increased by between 1 hour 12 minutes and 1 hour 30 minutes. For a printable version of this article click here. In order to refer to this article on its own click here.
E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News, please merely e-mail email@example.com with the message "subscribe". No form of identity is required. E-mail addresses are not used for any other purpose.
3rd May 2013 - New research
IS GENERIC MADOPAR AS GOOD AS MADOPAR ?
BMC Pharmacology and Toxicology  14 (1) : 24 (U.E.Gasser, A.Fischer, J.P.Timmermans, I.Arnet) Complete abstract
Madopar was compared against seven generic versions of Madopar to see if they were as good as Madopar. Madopar, which is for the treatment of Parkinson's Disease consists of L-dopa and benserazide, which helps to prevent the breakdown of L-dopa before it is made use of. It is therefore the equivalent of Sinemet. Madopar and Sinemet differ according to which countries they are available in. For more information go to Madopar. A generic version is supposed to be interchangeable. However, generic versions are often different from the original.
Every one of the seven generic versions of Madopar had one or two parameters outside the specifications of Madopar. Deviations for the active ingredients ranged from 8% more benserazide to 7% less L-dopa in two of the tablet formulations. Degradation products were measured in marked excess (26% more) in one capsule formulation, and so could pose a safety concern. Deviations for the active ingredients may go unnoticed by a new user of the generic product but may entail clinical consequences when switching over. The results therefore suggest caution when prescribing a generic version of Madopar or any other generic. For a printable version of this article click here. In order to refer to this article on its own click here.
27th April 2013 - New research
HEAD INJURY AND THE RISK OF PARKINSON'S DISEASE
Movement Disorders  Apr 22 [Epub ahead of print] (S.Jafari, M.Etminan,
The association of Parkinson's Disease and head trauma was 1.57 (1.35-1.83), meaning that head trauma causing concussion makes Parkinson's Disease more than one and half times more likely. So although head trauma makes Parkinson's Disease more likely it is not inevitable. Further analysis of the results might have shown that very severe head injury or certain types of head injury were largely responsible for the increased likelihood of Parkinson's Disease following head trauma. For a printable version of this article click here. In order to refer to this article on its own click here.
26th April2013 - New book
HANDBOOK OF PARKINSON'S DISEASE (Fifth edition)
Rajesh Pahwa (Editor), Kelly E. Lyons (Editor)
Publisher's description : This volume has long prevailed as one of the leading resources on Parkinson's disease. Fully updated with practical chapters on pathology, neurochemistry, etiology, and breakthrough research, it spans every essential topic related to the identification, assessment, and treatment of PD. Reflecting the many advances that have taken place in the management of PD, this volume promotes a multidisciplinary approach to care and supplies new sections on the latest pharmacologic, surgical, and rehabilitative therapies, as well as essential diagnostic, imaging, and nonmotor management strategies. New to this edition : Early identification of premotor symptoms, Potential disease modification agents, Physical and occupational therapy Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
20th April 2013 - News release
NEURTURIN FAILS CLINICAL TRIALS FOR PARKINSON'S DISEASE
Neurturin has failed to demonstrate any effect in Parkinson's Disease. Neurturin is administered using CERE-120, which is composed of a harmless adeno-associated virus (AAV) vector, which carries the gene for neurturin. Neurturin, which is naturally occurring, is known to repair damaged and dopamine-secreting neurons by restoring their function. Neurturin is a member of the same protein family as GDNF. CERE-120 is delivered by injection in to the brain. CERE-120 is produced by Ceregene Inc.
The clinical trial did not demonstrate statistically significant efficacy. Yet, following surgery, there was a marked placebo effect in those people being tested and even those not being tested, as there often is after surgical trials. The clinical trial was supported by the Michael J.Fox Foundation. The results suggest that it is unclear if Ceregene will move forward with the development of CERE-120 as a viable treatment for people with Parkinsonís Disease. For more information go to the News release. For a printable version of this article click here. In order to refer to this article on its own click here.
18th April2013 - New research
BRAIN CELL LOSS IN PARKINSON'S DISEASE
JAMA Neurology  70 (2) : 241-247 (D.A.Ziegler, J.S.Wonderlick, P.Ashourian, L.A.Hansen, J.C.Young, A.J. Murphy, C.K.Koppuzha, J.H.Growdon, S.Corkin) Complete abstract
For many years it has been widely claimed that, in Parkinson's Disease, there is a huge loss of the dopaminergic neurons (the brain cells that produce dopamine). It is often claimed that this cell loss is the primary cause of Parkinson's Disease. However, not a single study had ever actually shown that there was massive cell loss in Parkinson's Disease. It has also been assumed that loss of the dopaminergic neurons that can cause Parkinson's Disease precedes the loss of cholinergic neurons, which can lead to dementia, as is common in later Parkinson's Disease. However, the results of a study assessing this theory did not support what had often been claimed.
Researchers assessed the volume of the brain in the area in which dopaminergic neurons are common. They found that the volume of the brain in this area was decreased in people with mild Parkinson's Disease but not in people that did not have Parkinson's Disease. However, in more severe Parkinson's Disease there was no greater loss of volume of the brain in the area affected by Parkinson's Disease as there would have been if the severity of Parkinson's Disease was due to cell loss.Research has always instead been consistent with a major reduction in cell activity rather than an actual loss of the cells involved in Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
16th April2013 - New book
Publisher's description : As we get older there are few things more frightening than forgetting someone's name or where you left your house keys. For millions of us the first few times this happens we fear we're experiencing the onset of dementia. Recognizing the symptoms can lead to an early diagnosis which can mean better treatment options, a longer, better life and a change to take steps to slow or reduce the symptoms of dementia. There are many drugs and treatments the patient needs to retrain parts of their brain that have been damaged. You can DEFY it by learning the symptoms, getting diagnosed early, and getting treatment quickly. Diagnosis only takes 10 minutes. Ten minutes is all that stands between you and knowing if your lapse of memory is fatigue, a vitamin B deficiency, some other curable disease, or depression. Click here for more details.
13th April 2013 - New review
TECHNOLOGICAL DEVICES FOR PARKINSON'S DISEASE (Part 1)
In recent years technological devices have started being used to try to improve or aid people with Parkinson's Disease without the necessity for drugs or surgery :
LIGHT THERAPY consists of daily exposure to daylight, brighter artificial light, or to specific wavelengths of light. Light suppresses melatonin formation, which lowers dopamine activity. For more information go to Light therapy.
LASER DEVICES, including laser lights attached to canes, handheld devices or the Parkinson walkers. They display a beam of light on the ground, providing a target to step over to help overcome freezing episodes. For more information go to Laser cane and Laser Walker.
FUNCTIONAL ELECTRICAL STIMULATION is the use of electrical impulses to stimulate weak or paralysed muscles. For more information go to Functional electrical stimulation.
FOCUSED ULTRASOUND uses multiple intersecting beams of ultrasound energy are focused with a high degree of precision and accuracy on the target. For more information go to Focused Ultrasound.
MAGNETIC THERAPY involves the use of an extremely low-level electromagnetic field applied by a specially designed device, the Magnesphere. Helmholtz coils immerse the entire patient in a low strength electromagnetic field. For more information go to Magnetic therapy.
12th April 2013 - New web site
THE PARKINSON HUB
Theparkinsonhub is a recent Parkinson's Disease web site that aims to provide patients, carers and healthcare professionals with the latest news, link and information in the area of Parkinsonís disease. For more information, go to theparkinsonhub. They have just introduced the complementary PD Quality of Life interactive resource, which enables people with Parkinson's Disease to identify and understand those areas in their lives most affected by Parkinson's Disease. For more information go to pdqualityoflife.
6th April 2013 - New research
ISTRADEFYLLINE CLINICAL TRIAL RESULTS FOR PARKINSON'S DISEASE
Movement Disorders  Mar 11 [Epub ahead of print] (Y.Mizuno, T.Kondo, the
Japanese Istradefylline Study Group.
After a 12 week clinical trial using 20mg or 40mg istradefylline the change in daily OFF time was significantly reduced with 20mg per day and 40 mg per day. The daily OFF time was over 40 minutes less. However, the most common adverse event was dyskinesia, which occurred more commonly when taking istradefylline than when taking a placebo. For a printable version of this article click here. In order to refer to this article on its own click here.
5th April2013 - New book
AVOID 1-CLICK SHOPPING IF YOU HAVE PARKINSON'S
C. Michael Beetner
Publisher's description : Being diagnosed with Parkinsonís disease is always a very scary experience. What patients need is a guide that explains, in simple terms, what to expect and how to deal with the disease. The author, who was diagnosed in 1994, quickly became an advocate and worker in the Central Ohio Parkinsonís Society (COPS). COPS has always had a monthly newsletter giving him an opportunity to write monthly on the various aspects of the disease. This book is a compilation of the best columns over many years. All are written with a dry (and often off-beat) sense of humor. There are chapters on his deep brain surgery for Parkinsonís, treatment errors he has seen, and everything else from loosing the right to drive and Sex vs. PD. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
1st April 2013 - New research
INHALED DOPAMINE AGONIST CLINICAL TRIAL RESULTS
Acta Neurologica Scandinavica  Mar 26 [Epub ahead of print] (K.A.Grosset,
N.Malek, F.Morgan, D.G. Grosset)
Inhaled doses were gradually increased until efficacy was reached and given to patients when they were in an 'off' state. When it was inhaled, apomorphine was rapidly absorbed, within 2 to 7 minutes. This enabled a reversal from the 'off' state, in just 10 minutes. In contrast many people with Parkinson's Disease have to wait 30 to 60 minutes for their Parkinson's Disease drugs to have effect. Therefore, speed of effect appears to be its greatest benefit. Adverse effects did not differ between those taking inhaled apomorphine and those taking a placebo. For a printable version of this article click here. In order to refer to this article on its own click here.
30th March2013 - New book
PARKINSON'S TREATMENT : 10 SECRETS TO A HAPPIER LIFE
Michael S.Okun MD
Publisher's description : I never assume a sufferer or family member is aware of the ďsecretsĒ that may lead to hope and to a happier life. We must share these secrets, and this is the purpose of this book. Each chapter of this book reveals an important secret, and with each secret I will explain the insight, the rationale, the empiricism, and the science behind it. In each chapter I will also try to reveal a little more about myself, and a lot more about the patients and talented clinicians who gifted the Parkinson's secrets. These patients planted the seed of faith. They learned to grow hope, and they discovered the core values necessary to achieve happiness despite the chronic illness of Parkinson's disease. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
24th March 2103 - News release
NEW L-DOPA PRODUCT EXCEEDS THE EFFECT OF STALEVO
A new L-dopa product, which is presently called ODM-101, significantly decreased daily OFF-time without increasing ON-time with troublesome dyskinesias when compared to Stalevo, which is a standard medication in advanced Parkinson's Disease when people experience end-of-dose wearing off symptoms using L-dopa.
Stalevo contains three active substances in one tablet : L-dopa, plus carbidopa and entacapone, both of which help to maintain L-dopa levels. For more information go to Stalevo. ODM-101 has the same components as Stalevo but has a higher and fixed amount of carbidopa (either 65mg or 105 mg) regardless of the L-dopa dosage. As it made by the same manufacturers it is effectively an improved form of Stalevo.
People with Parkinson's Disease were given two forms of ODM-101 with two different amounts of carbidopa : ODM-101/65mg and ODM-101/105mg. Both of them reduced daily OFF-time more than Stalevo. ODM-101/105mg was marginally better than ODM-101/65mg. Similarly, both ODM-101 combinations increased the ON-time without troublesome dyskinesia significantly more than Stalevo. There were no significant differences between the treatments in ON-time with troublesome dyskinesia or in UPDRS II and III symptom scores. Overall, tolerability and safety of ODM-101 was comparable to that of Stalevo. For more information go to the News release. For a printable version of this article click here. In order to refer to this article on its own click here.
23rd March 2013 - New research
PIMAVANSERIN CLINICAL TRIAL RESULTS IN PARKINSON'S DISEASE
In a phase III clinical trial, Pimavanserin had effect in the treatment of psychosis in Parkinson's Disease. Parkinsonís Disease Psychosis usually consists of visual hallucinations and delusions. It is normally due to Parkinson's Disease drugs not Parkinson's Disease. It eventually occurs in up to 60% of people with Parkinson's Disease. Pimavanserin is an antagonist of serotonin 5-HT2A receptors. It is taken orally as a tablet once-a-day.
Patients took 40mg Pimavanserin for only six weeks. So its long term effects have not been assessed. The adverse events were little different from those found in people taking a placebo. Pimavanserin demonstrated significant antipsychotic efficacy and significant improvements in all secondary efficacy measures. Statistically significant benefits were also observed in exploratory measures of nighttime sleep, daytime wakefulness, and caregiver burden. For more information go to the News release. For a printable version of this article click here. In order to refer to this article on its own click here.
14th March 2013 - New research
BEING OVERWEIGHT IS MORE PREVALENT IN PARKINSON'S DISEASE
Arquivos de Neuropsiquiatra  70 (11) : 843-846 (H.Morales-BriceŮo, A.Cervantes-Arriaga, M.RodrŪguez-Violante, J.Calleja-Castillo, T.Corona) Complete abstract
Underweight and malnutrition are well documented in Parkinson's Disease (PD), while being overweight has been less reported. Researchers carried out a study comparing the weight and height of people with and without Parkinson's Disease. In those people with Parkinson's Disease only 1% were underweight, 33% were within the normal range, 47%% were overweight, and 19% were obese. Being normal weight and overweight were more prevalent in those people who had Parkinson's Disease when compared to those people who did not. Being obese and, even moreso, being underweight were more common in those people who did not have Parkinsons' Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
5th March 2013 - News release
CLINICAL TRIAL OF SUBCUTANEOUS L-DOPA FOR PARKINSON'S DISEASE
NeuroDerm announced today the results of a Phase I safety and pharmacokinetic trial of ND0612. ND0612 is a novel drug formulation for the treatment of Parkinsonís Disease. NeuroDerm is a pharmaceutical company that specializes in the development of novel dermal delivery routes for CNS drugs.
ND0612 is a combination of L-dopa and carbidopa, as is Sinemet, but it is a liquid formula administered continuously sub-cutaneously (via the skin) through a patch pump. It is designed to provide steady L-dopa blood levels for the reduction of motor complications in Parkinsonís Disease.
In this double-blind, placebo controlled, dose-escalation trial in young, healthy volunteers, ND0612 was shown to be safe and tolerable in all of the tested doses. Clinically meaningful L-dopa concentrations were reached. For the first time in humans, steady state L-dopa concentrations were maintained in a practical manner both day and night, thereby enabling more even levels of L-dopa than oral forms of L-dopa. The full results of this study will be presented at a future scientific meeting. For more information go to the News release For a printable version of this article click here. In order to refer to this article on its own click here.
4th March 2013 - New book
HOW TO LIVE WELL WITH PARKINSON'S : ADVICE FROM A PHYSICAL THERAPIST
Miriam P. Boelen
Publisher's description : People with Parkinsonís commonly have symptoms and problems unique to their condition that can interfere with daily activities. When initially diagnosed they all too often donít know what to do or where to turn. This book, written specifically for them, clears up questions they may have regarding their self-help. It gives step by step instructions in properly handling daily activities like walking, getting out of bed or chairs, and other potentially problematic everyday movements. It also guides them in finding the optimal medical team to help them stay well. For caregivers there are easy-to-follow instructions in safely assisting a person with PD without jeopardizing themselves or the one they are helping. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
3rd March 2013 - New survey
SURVEY OF THE CAUSES OF PARKINSON'S DISEASE
Parkinson's Database are conducting a survey of the causes of Parkinson's Disease. They believe that the mass accumulation of data for Physicians and Researchers will provide better treatments and faster diagnosis. They want to accumulate as much pertinent data on Parkinson's Disease and related diseases as possible. They believe that this data needs to come from the patients themselves in order to paint a much clearer picture of this disease for researchers. They do not want personal information. They believe that they will receive a much wider and more honest responses by providing anonymity. For more information go to Parkinson's Database For those interested in participating the survey is linked to on the left hand side of the page. In order to refer to this article on its own click here.
18th February 2013 - News release
COGANE FAILS CLINICAL TRIALS FOR PARKINSON'S DISEASE
Phytopharm announced the results of the Phase II, randomised, double blind, placebo controlled, dose-ranging trial of Cogane in unmedicated patients with early-stage Parkinsonís Disease. Cogane was found to have no beneficial effects at all on Parkinson's Disease symptoms. For more information go to the News release
Cogane, which can be taken orally, readily crosses the blood-brain barrier and has been shown to stimulate the release of GDNF. GDNF can indirectly stimulate the formation of dopamine, the substance whose insufficiency causes Parkinson's Disease. However, GDNF deficiency has never been shown to be the cause of Parkinson's Disease. Previous studies claiming efficacy for Cogane in Parkinson's Disease were only carried out in Macaque monkeys who did not actually have Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
15th February 2013 - New research
DBS IS EFFECTIVE IN EARLIER PARKINSON'S DISEASE
New England Journal of Medicine  368 (7) : 610-622 (Schuepbach WM, Rau J,
Knudsen K, Volkmann J, Krack P, Timmermann L, Hšlbig TD, Hesekamp H, Navarro SM,
Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A,
Gruber D, Schneider GH, Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel
Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto JL, Bataille B, MaltÍte D,
Damier P, Raoul S, Sixel-Doering F, Hellwig D, Gharabaghi A, KrŁger R, Pinsker
MO, Amtage F, Rťgis JM, Witjas T, Thobois S, Mertens P, Kloss M, Hartmann A,
Oertel WH, Post B, Speelman H, Agid Y, Schade-Brittinger C, Deuschl G; EARLYSTIM
In a two year clinical trial people with Parkinson's Disease and early motor complications (with an average age of 52 and a mean duration of Parkinson's Disease of 7.5 years) underwent neurostimulation plus medical therapy or only medical therapy alone. The primary end point was quality of life, as assessed with the use of the Parkinson's Disease Questionnaire (PDQ-39) with scores ranging from 0 to 100 and higher scores indicating worse function.
For the primary outcome of quality of life, the mean score for the neurostimulation group improved by 7.8 points, and that for the medical-therapy group worsened by 0.2 points. Neurostimulation was superior to medical therapy with respect to motor disability, activities of daily living, L-dopa induced motor complications, and time with good mobility and no dyskinesia. Serious adverse events occurred in 54% of the people in the neurostimulation group and in 44% of those in the medical therapy group. Serious adverse events related to surgical implantation or the neurostimulation device occurred in 17% of people. For a printable version of this article click here. In order to refer to this article on its own click here.
14th February 2013 - New research
MOLECULAR HYDROGEN WATER FOR PARKINSON'S DISEASE
Movement Disorders  Feb 11 (A.Yoritaka, M.Takanashi, M.Hirayama, T.Nakahara, S.Ohta, N.Hattori, D.Weintraub, K.Papay, A.Siderowf) Complete abstract
Oxidative stress is involved in the progression of Parkinson's Disease. Recent studies have confirmed that molecular hydrogen (H2) functions as a highly effective antioxidant in cultured cells and animals.
Drinking molecular hydrogen dissolved water had reduced oxidative stress and improved Parkinson's Disease features in animals. A pilot study was carried out in people with Parkinson's Disease who were taking L-dopa. Each person drank either a litre a day of molecular hydrogen water or only water (without the molecular hydrogen). Symptom scores improved in those people who drank molecular hydrogen water and worsened in those people who only drank normal water. The drinking of molecular hydrogen water was found to safe and well tolerated. It would therefore be an easy means of delaying or reducing symptoms. A larger clinical trial is intended. For a printable version of this article click here. In order to refer to this article on its own click here.
8th February 2013 - News release
POSITIVE RESULTS CLAIMED FOR STEM CELLS IN PARKINSON'S DISEASE
International Stem Cell Corporation have claimed positive results from its pre-clinical study using stem cells in the treatment of Parkinson's Disease. The primary goal of the study was to demonstrate the benefits of neuronal cells derived from human stem cells. The neuronal cells were derived from human parthenogenetic stem cells, which are not obtained via reproduction. They can become neurons when they are implanted in to the brain.
The study was carried out for 12 weeks on rats who did not actually have Parkinson's Disease. The rats were instead given 6-OHDA (6-Hydroxydopamine), which is a toxin used to kill dopaminergic neurons (the cells involved in Parkinson's Disease). The actual results for the study have not been disclosed. It has only been stated that "signs of improvement in rotational behavior of these animals were clearly observed." For more information go to the News release
Although it was claimed for many years that stem cells could rid Parkinson's Disease, stem cell operations have not fulfilled those claims. It was widely believed that stem cell operations were essential because there was a massive loss of cells involved in Parkinson's Disease. However, no study has ever demonstrated massive cell loss in Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
6th February 2013 - New book
SO I'VE GOT PARKINSON'S DISEASE
Publisher's description : Terry Rummins was diagnosed with Parkinson's 10 years ago. So, I've Got Parkinson's Disease is her story and covers her diagnosis and the progression of the condition - from the first warning tremors in her right hand to her day-to-day life now. Terry has written this book in the hope that describing her experience will benefit others who have been diagnosed with Parkinson's and to help them understand their expectations of how the condition may affect them. This is a candid story, told with humour and contains a positive message for those recently diagnosed and those close to them. It is also for anyone interested in what happens when life presents an unpleasant surprise. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
29th January 2013 - New research
USING CELL PHONES TO MONITOR PARKINSON'S DISEASE
IEEE Transactions on Biomedical Engineering (submitted)  (A.Tsanas, M.A.Little, P.E.McSharry, L.O. Ramig) Complete abstract
Dysphonia is an impairment in the ability to produce vocal sounds that can occur in Parkinson's Disease. A wide range of dysphonia measures have been used to predict Parkinson's Disease severity using speech signals. Researchers demonstrated that this method can match standard methods of diagnosing Parkinson's Disease.
Telephone monitoring of Parkinsonís Disease has attracted interest as a potential means of assessing this. Purpose built devices have been developed that record various signals that can be associated with symptom severity, as quantified on standard Parkinson's Disease scores such as the Unified Parkinsonís Disease Rating Scale (UPDRS). Previous studies have demonstrated replication of UPDRS scores to within less than 2 points of a clinical ratersí assessment of symptom severity, using solely high-quality speech signals.
This study investigated using the cellular mobile telephone networks for Parkinson's Disease monitoring. The Parkinson's Disease (UPDRS) symptom score could be estimated to within about 3.5 points difference from the cliniciansí assessment, which is useful because even different clinicians vary by as much as 4 to 5 points. This provides evidence that the phone network is adequate for inexpensive, mass-scale Parkinson's Disease symptom monitoring. For a printable version of this article click here. In order to refer to this article on its own click here.
28th January 2013 - New book
THE ESSENTIAL DYSPHAGIA HANDBOOK : REAL LIFE DECISIONS, MINDMAPPING AND MORE
Dr Claire Langdon, Karen Jardine, Dr Julie Cichero
Dysphagia is difficulty in swallowing and occurs in many people with Parkinson's Disease. Publisher's description : The goal of this book is to fill a gap that currently exists between the theoretical learning that takes place in the university setting, and practical management of clients in the workplace. Dysphagia is becoming an increasingly large part of the work done by Speech Language Pathologists. We wanted to provide a resource that helps to bridge the gaps between theoretical learning and hands-on practice and provide a resource that unpacks clinical reasoning and helps new clinicians think about how and why recommendations about managing clients with dysphagia are made. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
12th January 2013 - New research
PARKINSON'S DISEASE DOES NOT CAUSE COMPULSIONS
Neurology  80 (2) : 176-180 (Weintraub D, Papay K, Siderowf A) Complete abstract
Although compulsions can often occur in Parkinson's Disease, Parkinson's Disease does not actually cause compulsions or related problems. When people with Parkinson's Disease were compared with people who do not have Parkinson's Disease the frequencies of compulsions were little different : gambling (1.2% v 0.7%), buying (3% v 2%), sexual behaviour (4.2% v 3.5%), eating (7% v 10%), punding (prolonged, purposeless, and stereotyped behaviour) (5% v 2%), hobbyism (5% v 12%), walkabout (0.6% v 0.7%), any compulsions (18% v 20%).
The fact that Parkinson's Disease itself does not seem to cause an increased risk of developing compulsions or related behaviour further reinforces the reported association between Parkinson's Disease drugs and causing compulsions. Given that approximately 20% of people with newly diagnosed Parkinson's Disease report some impulse control or related behaviour symptoms, long-term follow-up is needed to determine whether such people are at increased risk for impulse control disorder development once Parkinson's Disease drugs are initiated. For a printable version of this article click here. In order to refer to this article on its own click here.
11th January 2013 - News release
SALIVA GLAND TEST FOR PARKINSON'S DISEASE
New research has suggested that testing a portion of a person's saliva gland may be a means of diagnosing Parkinson's Disease. It was previously shown in autopsies of people with Parkinson's Disease that the abnormal proteins associated with Parkinson's are consistently found in the submandibular saliva glands, which are found under the lower jaw.
The study involved 15 people with an average age of 68 who had Parkinson's disease for an average of 12 years, who responded to Parkinson's medication and who did not have known saliva gland disorders. Biopsies were taken of two different saliva glands. The abnormal Parkinson's protein was detected in nine of the 11 patients who had enough tissue to study. This is the first study demonstrating the value of testing a portion of the saliva gland to diagnose a living person with Parkinson's Disease. For more information go to the News release For a printable version of this article click here. In order to refer to this article on its own click here.
|GO TO DECEMBER 2012|
ARCHIVESJuly August September October November December March April May June July August September October November December March April May June July August September October November December